Table 2.
Number and proportion of digestive system cancer-related adverse event reports for ranitidine and PPIs and H2 antagonists and associated proportional reporting ratios and 95% confidence intervals.
| Type of Cancer | Ranitidine (N = 13,856) |
PPIs and Other H2 Antagonists (N = 128,107) |
Proportional Reporting Ratio (95% Confidence Interval) |
p-Value |
|---|---|---|---|---|
| N (%) | N (%) | |||
| All | 282 (2.00) | 712 (0.56) | 3.66 (3.19–4.20) | <0.0001 |
| Mouth | 3 (0.02) | 34 (0.03) | 0.82 (0.25–2.66) | 1.00 |
| Pharynx | 3 (0.02) | 3 (0.00) | 9.24 (1.87–45.80) | 0.01 |
| Esophagus | 47 (0.34) | 122 (0.10) | 3.56 (2.54–4.98) | <0.0001 |
| Stomach | 46 (0.33) | 288 (0.22) | 1.48 (1.08–2.01) | 0.02 |
| Small intestine | 1 (0.01) | 9 (0.01) | 1.03 (0.13–8.11) | 1.00 |
| Colon/rectum | 157 (1.13) | 89 (0.07) | 16.31 (12.58–21.14) | <0.0001 |
| Anus | 1 (0.01) | 2 (0.00) | 4.62 (0.42–50.98) | 0.27 |
| Gallbladder | 2 (0.01) | 4 (0.00) | 4.62 (0.85–25.24) | 0.11 |
| Liver | 30 (0.22) | 105 (0.08) | 2.64 (1.76–3.96) | <0.0001 |
| Pancreas | 20 (0.14) | 85 (0.07) | 2.18 (1.34–3.54) | 0.004 |